BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18854267)

  • 21. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.
    Montgomery E; Bronner MP; Goldblum JR; Greenson JK; Haber MM; Hart J; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Toledano AY; Shyr Y; Washington K
    Hum Pathol; 2001 Apr; 32(4):368-78. PubMed ID: 11331953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions.
    Geddert H; Zeriouh M; Wolter M; Heise JW; Gabbert HE; Sarbia M
    Am J Clin Pathol; 2002 Jul; 118(1):60-6. PubMed ID: 12109857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical expression of cell-cycle proteins in gastric precancerous lesions.
    Anagnostopoulos GK; Stefanou D; Arkoumani E; Karagiannis J; Paraskeva K; Chalkley L; Habilomati E; Tsianos E; Agnantis NJ
    J Gastroenterol Hepatol; 2008 Apr; 23(4):626-31. PubMed ID: 18397488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.
    Li H; Zhang L; Lou H; Ding I; Kim S; Wang L; Huang J; Di Sant'Agnese PA; Lei JY
    Am J Clin Pathol; 2005 Aug; 124(2):282-7. PubMed ID: 16040301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
    Cuatrecasas M; Catasus L; Palacios J; Prat J
    Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
    Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
    Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes.
    Skálová A; Sima R; Vanecek T; Muller S; Korabecna M; Nemcova J; Elmberger G; Leivo I; Passador-Santos F; Walter J; Rousarova M; Jedlickova K; Curik R; Geierova M; Michal M
    Am J Surg Pathol; 2009 Aug; 33(8):1137-45. PubMed ID: 19461506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus.
    Shi XY; Bhagwandeen B; Leong AS
    Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):447-52. PubMed ID: 18665038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of cyclin A immunohistochemistry for cancer risk stratification in Barrett esophagus surveillance: A multicenter case-control study.
    van Olphen SH; Ten Kate FJC; Doukas M; Kastelein F; Steyerberg EW; Stoop HA; Spaander MC; Looijenga LHJ; Bruno MJ; Biermann K;
    Medicine (Baltimore); 2016 Nov; 95(47):e5402. PubMed ID: 27893678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histological assessment & use of immunohistochemical markers for detection of dysplasia in Barrett's esophageal mucosa.
    Kinra P; Gahlot GPS; Yadav R; Baloda V; Makharia GK; Gupta SD; Das P
    Pathol Res Pract; 2018 Jul; 214(7):993-999. PubMed ID: 29764708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
    Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
    Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant p53 expression is associated with neoplastic progression in Barrett oesophagus diagnosed as indefinite for dysplasia.
    Chen X; Liu BL; Harpaz N; Zhu H; Polydorides AD; Liu Q
    Histopathology; 2023 Feb; 82(3):454-465. PubMed ID: 36251540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of p53 protein expression in Barrett esophagus.
    Krothapalli M; Kini JR; Kini H; Sahu KK; Shenoy S; Krishna SG; Tantry BV
    Indian J Pathol Microbiol; 2018; 61(2):170-175. PubMed ID: 29676351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using a combination of cytochrome P450 1B1 and beta-catenin for early diagnosis and prevention of colorectal cancer.
    Chang H; Su JM; Huang CC; Liu LC; Tsai CH; Chou MC; Lin P
    Cancer Detect Prev; 2005; 29(6):562-9. PubMed ID: 16289386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of human carcinoma-associated antigen in esophageal adenocarcinoma and its precursor lesions.
    Liang S; Yao J; Bourne PA; diSant'Agnese PA; Huang J; Lei JY
    Am J Clin Pathol; 2004 Nov; 122(5):747-51. PubMed ID: 15491971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus.
    Villanacci V; Bellone G; Battaglia E; Rossi E; Carbone A; Prati A; Verna C; Niola P; Morelli A; Grassini M; Bassotti G
    Hum Pathol; 2008 Mar; 39(3):403-9. PubMed ID: 18261624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 Mutation analysis of low-grade dysplasia and high-grade dysplasia/carcinoma in situ of the esophagus using laser capture microdissection.
    Kobayashi M; Kawachi H; Takizawa T; Uchida K; Sekine M; Kumagai J; Momma K; Nemoto T; Akashi T; Funata N; Eishi Y; Koike M
    Oncology; 2006; 71(3-4):237-45. PubMed ID: 17652955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia.
    Sagatys E; Garrett CR; Boulware D; Kelley S; Malafa M; Cheng JQ; Sebti S; Coppola D
    Hum Pathol; 2007 Oct; 38(10):1526-31. PubMed ID: 17640711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.